Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003351 · ClinicalTrials.gov registry record · Phase 2
Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00003351 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 104 participants.
The verdict
NCT00003351, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of irinotecan in treating patients who have refractory metastatic breast cancer.
Interventions
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 1998-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003351
The ClinicalTrials.gov registry entry for NCT00003351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which irinotecan hydrochloride is the first listed.
NCT00003351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003351 about?
NCT00003351 is a clinical study titled "Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of irinotecan in treating patients who have refractory metastatic breast cancer.
What is the current status of trial NCT00003351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 1998-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00003351?
The interventions under investigation include: irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003351?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.